Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Genprex, Inc.

  • AUSTIN, Texas
  • Public · NASDAQ: GNPX
  • 13 employees
$6.8MMarket cap
$0Revenue · FY2024
-$16.2MNet income
13Employees
GNPXNASDAQ
2018IPO

About Genprex, Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2024
$0
Net income
-$16.2M
Total assets
$10.2M
Market cap
$6.8M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: GNPX

15-minute delayed · data by Polygon.io

Market cap
$6.8M
Open
Day range
Prev close
Volume
IPO date
Mar 29, 2018

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Genprex, Inc..

Write a review
Explore

Similar companies

Browse all →